Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study

OBJECTIVE: Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) is approved for the treatment of patients aged ≥6 years with attention-deficit/hyperactivity disorder (ADHD). A pivotal double-blind (DB) study of children aged 6–12 years with ADHD demonstrated efficacy for ADHD with good tolerability....

Descripción completa

Detalles Bibliográficos
Autores principales: Childress, Ann C., Marraffino, Andrea, Cutler, Andrew J., Oh, Charles, Brams, Matthew N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031142/
https://www.ncbi.nlm.nih.gov/pubmed/36809150
http://dx.doi.org/10.1089/cap.2022.0076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10031142/
https://www.ncbi.nlm.nih.gov/pubmed/36809150
http://dx.doi.org/10.1089/cap.2022.0076

Ejemplares similares